Nucleoside analogs in combination therapy of herpes simplex infections

Abstract

A pharmaceutical product comprising a nucleoside analogue active against herpes simplex virus, such as acyclovir/valaciclovir or penciclovir/famciclovir, and an immunosuppressant, as a combined preparation for simultaneous, separate or sequential use in the treatment and/or prevention of herpes simplex virus infections.

1 . A pharmaceutical product comprising a nucleoside analogue active against herpes simplex virus, and an immunosuppressant, as a combined preparation for simultaneous, separate or sequential use in the treatment and/or prevention of herpes simplex virus infections.  
     
     
         2 . A method of treatment and/or prophylaxis of herpes simplex virus infections, which comprises administering to a human or animal subject, a nucleoside analogue active against herpes simplex virus, and an immunosuppressant or a pharmaceutically acceptable salt or ester thereof.  
     
     
         3 . The use of a nucleoside analogue antiviral active against herpes simplex virus, for the manufacture of a medicament for administration in conjunction with an immunosuppressant or a pharmaceutically acceptable salt or ester thereof, for the treatment and/or prevention of herpes simplex virus infections.  
     
     
         4 . A product, method, or use according to  claim 1 ,  2  or  3 , wherein the nucleoside analogue is acyclovir/valaciclovir or penciclovir/famciclovir.  
     
     
         5 . A product, method, or use according to  claim 1 ,  2 ,  3 , or  4 , wherein the immunosuppressant is a cytotoxic agents, a corticosteroid, or a non-steroidal anti-inflammatory agent.  
     
     
         6 . A product, method, or use according to  claim 5  wherein the immunosuppressant is cyclophosphamide, cyclosporin A, hydrocortisone, or dexamethasone.